General Notices

• NIAID Funded Extensions for Career Award Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19
  (NOT-AI-21-051)
  National Institute of Allergy and Infectious Diseases
  

• NIAID Funded Extensions for Fellowship Award Recipients Whose Career Trajectories Have Been Significantly Impacted by COVID-19
  (NOT-AI-21-052)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Pre-Application Webinar for RFA-CA-21-031, Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO; U01 Clinical Trial Required) and RFA-CA-21-032, (ENICTO Coordinating Center; U24 Clinical Trial Not Allowed)
  (NOT-CA-21-078)
  National Cancer Institute
  

• Notice of Information: Establishment of a Standard THC Unit to be used in Research
  (NOT-DA-21-049)
  National Institute on Drug Abuse
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute of Mental Health
  

• Notice of NIDA's participation in NOT-NS-21-049, "Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities"
  (NOT-DA-21-053)
  National Institute on Drug Abuse
  

• Notice of NIBIB Participation in PAR-21-166 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)"
  (NOT-EB-21-011)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of NIBIB Participation to PA-20-194 "NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)"
  (NOT-EB-21-015)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of NIBIB Participation to PA-20-195 "NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)"
  (NOT-EB-21-016)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Correction to Eligibility Information of RFA-MH-21-180, "BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed)"
  (NOT-MH-21-280)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice of Early Termination of PAR-21-159, Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06 Clinical Trial Not Allowed)
  (NOT-OD-21-112)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  

• Notice of Technical Assistance Webinar for NOT-OD-21-087, Developing and Testing Multilevel Physical Activity Interventions to Improve Health and Well-Being NOSI
  (NOT-OD-21-120)
  Office of Disease Prevention
  

• Request for Information (RFI): Drinking Water Contaminants of Emerging Concern for National Emerging Contaminant Research Initiative
  (NOT-ES-21-006)
  National Institute of Environmental Health Sciences
  

• Request for Information (RFI) on Flexibilities to Reduce Administrative Burden While Continuing to Apply the PHS Policy to Zebrafish Immediately After Hatching
  (NOT-OD-21-118)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice to Include AIDS Receipt Dates in PAR-21-109 "Early Stage Investigator Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)"
  (NOT-AG-21-024)
  National Institute on Aging
  

• Notice of Change in Key Dates for RFA-AI-20-077, Immune Development in Early Life (IDEaL) (U01 Clinical Trial Not Allowed)
  (NOT-AI-21-048)
  National Institute of Allergy and Infectious Diseases
  National Institute of Environmental Health Sciences
  

• Notice of Correction of Key Dates for PAR-20-284, Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)
  (NOT-CA-21-077)
  National Cancer Institute
  

• Notice of Change to the Eligibility Information for RFA-DA-22-001, "Mobile Health Solutions to rectify digital inequality in communities affected by drug addiction (R43/R44 Clinical Trial Optional)"
  (NOT-DA-21-051)
  National Institute on Drug Abuse
  

• Notice of Change to NOT-EB-21-005 "NIBIB Guidance for Support of Clinical Trial Applications"
  (NOT-EB-21-017)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice of Requirement for Submission of Current and Pending Support Information for the PD(s)/PI(s) of PAR-20-175 Institutional Development Award (IDeA) Networks for Clinical and Translational Research (IDeA-CTR) (U54 Clinical Trial Optional)"
  (NOT-GM-21-049)
  National Institute of General Medical Sciences
  

• Notice of NICHD Participation in RFA-AI-20-078 "Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)"
  (NOT-HD-21-030)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Clarification of Eligibility of Applicant Organizations for RFA-HD-22-013: Population Dynamics Centers Research Infrastructure Program FY 2022 (P2C Clinical Trial Not Allowed)
  (NOT-HD-21-033)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Change to Additional Information for NOT-OD-21-094 "Notice of Special Interest (NOSI): Administrative Supplements to Support Collaborations to Improve the AI/ML-Readiness of NIH-Supported Data"
  (NOT-OD-21-119)
  National Institutes of Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 - Clinical Trial Not Allowed)
  (NOT-CA-21-075)
  National Cancer Institute
  

• Notice of Intent to Publish: Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 - Clinical Trial Not Allowed)
  (NOT-CA-21-076)
  National Cancer Institute
  

Notices of Special Interest

• Notice of Special Interest: Public Policy Effects on Alcohol-, Cannabis-, Tobacco-, and Other Drug-Related Behaviors and Outcomes
  (NOT-AA-21-028)
  National Institute on Alcohol Abuse and Alcoholism
  National Cancer Institute
  National Institute on Drug Abuse
  

• Notice of Special Interest (NOSI): Biology of Lung and Head and Neck Preneoplasia
  (NOT-CA-21-057)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Early-life Factors and Cancer Development Later in Life
  (NOT-CA-21-074)
  National Cancer Institute
  

• Notice of Special Interest (NOSI): Administrative Supplements to Support Addiction Science and Related Neuroscience Pilot Research Projects at NIMHD-Funded Research Centers in Minority Institutions (RCMI)
  (NOT-MD-21-022)
  National Institute on Minority Health and Health Disparities
  National Institute on Drug Abuse
  

• RESCINDED - Notice of Special Interest (NOSI): NIH Research Project Grant (R01) Applications from Individuals from Diverse Backgrounds, Including Under-Represented Minorities
  (NOT-NS-21-049)
  National Institute of Neurological Disorders and Stroke
  National Institute on Alcohol Abuse and Alcoholism
  National Institute on Drug Abuse
  

Funding Opportunities

• NeuroNEXT Clinical Trials (U01 Clinical Trial Optional)
  (PAR-21-223)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
  (PAR-21-224)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Standard dates apply *** Note new SBIR/STTR Standard Due Dates.
  
  

• NIMH Research Education Mentoring Program for HIV/AIDS Researchers (R25 Clinical Trial Not Allowed)
  (PAR-21-228)
  National Institute of Mental Health
  Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date(s) listed below.
  
  

• Screening and Functional Validation of Human Birth Defects Genomic Variants (R01 Clinical Trial Not Allowed)
  (PAR-21-229)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute of Dental and Craniofacial Research
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NINDS Exploratory Clinical Trials (U01 - Clinical Trial Required)
  (PAR-21-236)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Limited Competition: Development and Renovation of Research Space for HIV/AIDS Research at Institutions Serving Underrepresented Populations or Located in Institutional Development Award (IDeA)-eligible States (C06 Clinical Trial Not Allowed)
  (PAR-21-238)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Application Receipt Date(s): Not Applicable
  
  

• Consortium for Innovative HIV/AIDS Vaccine and Cure Research (UM1 Clinical Trial Not Allowed)
  (RFA-AI-21-039)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): Not Applicable
  
  

• Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01 Clinical Trial Required)
  (RFA-CA-21-031)
  National Cancer Institute
  Application Receipt Date(s): July 14, 2021
  
  

• Coordinating Center for Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U24 Clinical Trial Not Allowed)
  (RFA-CA-21-032)
  National Cancer Institute
  Application Receipt Date(s): July 14, 2021
  
  

• Standardization of C-Peptide and HbA1C Measurements Program (U01 Clinical Trial Not Allowed)
  (RFA-DK-21-007)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): October 20, 2021
  
  

• Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)
  (RFA-DK-21-011)
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 9, 2022 and October 7, 2022
  
  

• Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trials Not Allowed
  (RFA-FD-21-032)
  Food and Drug Administration
  Application Receipt Date(s): July 6, 2021 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
  

• Human Milk as a Biological System (R01 Clinical Trial Optional)
  (RFA-HD-22-020)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 29, 2021
  
  

• NHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
  (RFA-HL-23-004)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
  (RFA-HL-23-005)
  National Heart, Lung, and Blood Institute
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Research Program Award (R35 Clinical Trial Optional)
  (RFA-NS-21-020)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): July 13, 2021
  
  

• BRAIN Initiative: Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UG3/UH3 Clinical Trial Optional)
  (RFA-NS-21-023)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• BRAIN Initiative: Clinical Studies to Advance Next-Generation Invasive Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
  (RFA-NS-21-024)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Mental Health
  Application Receipt Date(s): Multiple dates, see announcement.